Unique ID issued by UMIN | UMIN000021389 |
---|---|
Receipt number | R000024667 |
Scientific Title | Effects of late-onset hypogonadosm syndrome in prognosis of COPD; prospective, multicenter study |
Date of disclosure of the study information | 2016/03/09 |
Last modified on | 2020/02/28 12:03:10 |
Effects of late-onset hypogonadosm syndrome in prognosis of COPD; prospective, multicenter study
Effects of LOH syndrome in prognosis of COPD
Effects of late-onset hypogonadosm syndrome in prognosis of COPD; prospective, multicenter study
Effects of LOH syndrome in prognosis of COPD
Japan |
COPD stage2-3
Pneumology |
Others
NO
To analyze an effects of LOH syndrome on FEV1 secular change of more than 60-year-old males with COPD in prognosis of COPD. Farther, changes of skeletal muscle weakness, loss of deterioration in nutritional status, body composition, calorific value and quality of life, and the correlation between FEV1 and these factors.
Others
Search of biomarkers
Exploratory
Pragmatic
Not applicable
secular change of FEV1 with LOH syndrome
secular change
1.respiratory function(VC, %VC, FVC, FEV1, FEV1%, RV, DLCO)
2.skeletal muscle mass
3.nutritional status(height, weight, BMI, TP, Alb)
4.body composition(body cell mass, body fat, body fat percentage, lean body mass, extracellular intracelullar (TBW), moisture content (ECW))
5.calorific value(basal metabolic rate)
6.inflammation(high-sensitivity CRP)
7.quality of life
8.the correlation between skeletal, muscle mass, nutritional status, body composition, calorific value and quality of life, and FEV1
9.morbidity of LOH syndrome
10.background factor of LOH syndrome
11.effect of LOH syndrome on change of FEV1, skeletal, muscle mass, nutritional status, body composition, calorific value and quality of life
Observational
60 | years-old | <= |
Not applicable |
Male
1)Diagnosed COPD by spirometry
2)Treated for COPD
3)COPD stage2-3
4)More than 60-year-old
5)Male
6)State that patient can visit a hospital
7)Getting the informed consent by patient or amanuensis
1)Advanced dementia
2)Performed tracheotomy
3)Acute respiratory failure
4)COPD acute exacerbation within 3 months and received oral or intravenous steroid treatment
5)Having a complication of malignancy terminally
6)Female
7)Treated or scheduled androgen therapy
8)Having an interstitial pneumonia and diagnosed with combined pulmonary fibrosis and emphysema
9)Asthma attack within 3 months and received oral or intravenous steroid treatment
10)Treated with home oxygen therapy
11)Reseachers considered not to be suitable for stury
150
1st name | |
Middle name | |
Last name | Manabu Ueno |
National Hospital Organization Takasaki General Medical Center
Respiratory Medicine
36 Takamatsu-cho, Takasaki-city, Gunma
+81273225901
manabun0825@gmail.com
1st name | |
Middle name | |
Last name | Manabu Ueno |
National Hospital Organization Takasaki General Medical Center
Respiratory Medicine
36 Takamatsu-cho, Takasaki-city, Gunma
+81273225901
manabun0825@gmail.com
National Hospital Organization Takasaki General Medical Center
NHO network study
Japan
NO
2016 | Year | 03 | Month | 09 | Day |
Unpublished
Terminated
2016 | Year | 01 | Month | 19 | Day |
2016 | Year | 01 | Month | 19 | Day |
2016 | Year | 02 | Month | 23 | Day |
2017 | Year | 11 | Month | 30 | Day |
Study design: prospective cohort study
Subject: patients visited in a hospital during the 2016-2018 and to meet all inclusion criteria
Measurement item: patient information, physical findings, physiological function test, imaging test, laboratory test, muscle measurements, body composition, questionnaire
2016 | Year | 03 | Month | 08 | Day |
2020 | Year | 02 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024667